Parthenolide cytotoxicity increased in combination with arsenic trioxode in mt2 lymphoma cells

Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell lymphoma caused by human T-cell leukemia/lymphoma virus type1 (HTLV-1). Iran, especially Khorasan province, is known as one of theendemic regions for HTLV-1. Despite advances in the treatment of ATLL, the average survival rate of this malignancy is low. Parthenolide is a sesquiterpene lactone with broad-spectrum anticancer andantiproliferative activities. To introduce more effective anticancer strategies against ATLL, here we investigate whether parthenolide could enhance the efficacy of arsenic trioxide, a chemical drug prescribed for ATLL. In this regard, at first MT-2 cells, an ATLL cell line, were treated with increasing concentrations of parthenolide (1.25, 2.5 and 5 μg/ml) and arsenic (1, 2, 4 and 8 μg/ml) for 24, 48 and 72 h, and the IC50 value of drugs was determined. Then, cells were treated with a combination of parthenolide (1 and 2 μg/ml) and arsenic (1 and 2 μg/ml) for 72 h. Finally, the viability of cells was measured by Alamar blue test, and apoptosis was determined by PI staining and flow cytometry. Obtained results indicated that 1 μg/ml parthenolide increased the toxicity of 2 μg/ml arsenic, and therefore, had synergic effects with this anticancer drug. In conclusion, current findings suggest that combinatorial use of parthenolide and arsenic can be helpful in ATLL treatment.

کلیدواژه ها:

Blood Cancer ، Cell and Cancer ، Cancer Treatment and Management ، Targeted Cancer Therapy ، Drugs and Cancer